click on circles to display study description...

Khamis, 2020

favipiravir plus interferon (n=44) vs. standard of care (n=45)

randomized controlled trial

favipiravir with interferon beta-1b by inhalation aerosol
favipiravir : 1600 mg (Day 1) followed by 600mg twice a day for a maximum of 10 daysinterferon beta-1 : 8million IU (0.25µg) twice a day for 5 days (through nebulization)

standard of care
HCQ 400 mg twice per day on the day 1, then 200 mg twice per day for 7 days

COVID-19 mild to moderate

open label

1 center, Oman

200 patients needed; due to logistical and financial constraints, only a total of 89 COVID-19 patients were enrolled into the study